Structure Therapeutics Doses First Patients in Phase 3 ACCOMPLISH Program, Bolstered by $1.3B Cash Runway

Structure Therapeutics Doses First Patients in Phase 3 ACCOMPLISH Program, Bolstered by $1.3B Cash Runway

On August 6, 2026, Structure Therapeutics Inc. (NASDAQ: GPCR) achieved a defining clinical milestone, announcing that the first patients have been dosed in its Phase 3 ACCOMPLISH program (evaluating ACCOMPLISH-1 and ACCOMPLISH-2). The program is designed to support global regulatory submissions for once-daily oral aleniglipron (GSBR-1290) in chronic weight management. Alongside this clinical initiation, Structure reported its Q2 2026 financial results, highlighting a robust cash position that secures its operations through 2028.

Q2 2026 Financial Position and Cash Runway

Structure remains pre-revenue and heavily invested in clinical development, reporting:

• Net Loss: $106.2 million for the second quarter of 2026.
• Cash and Liquidity: $1.3 billion in cash, cash equivalents, and short-term investments as of June 30, 2026.
• Runway: This cash balance is projected to fund operations and key clinical milestones through the end of 2028, covering the ongoing ACCESS open-label extension (OLE), ACCESS II extension, supplementary studies, and the full Phase 3 ACCOMPLISH registrational program. It excludes pre-commercialization and commercial manufacturing costs.

Upcoming Milestones in H2 2026 (Q4 2026)

Structure has a catalyst-rich second half of 2026, with key supplementary clinical trial readouts expected in Q4 2026:

1. Body Composition Trial: A 44-week clinical trial evaluating the effect of oral aleniglipron on body fat loss.
2. SWITCH Trial: A 12-week clinical trial evaluating the safety, tolerability, and efficacy of transitioning patients from approved injectable GLP-1 receptor agonists (such as Wegovy or Zepbound) to once-daily oral aleniglipron for long-term weight loss maintenance.
3. Oral Amylin Combination Program: Following positive preclinical data presented at the American Diabetes Association (ADA) meeting in June 2026—which showed that combining aleniglipron with ACCG-2671 (an oral small molecule amylin receptor agonist) resulted in superior weight loss compared to monotherapy¹—Structure plans to initiate a combination clinical trial in Q4 2026.